Hassan Sadozai
Overview
Explore the profile of Hassan Sadozai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
256
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sadozai H, Acharjee A, Kayani H, Gruber T, Gorczynski R, Burke B
Front Immunol
. 2024 Mar;
15:1360629.
PMID: 38510243
Introduction: Pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, is a particularly lethal disease that is often diagnosed late and is refractory to most forms of treatment....
2.
Sadozai H, Rojas-Luengas V, Farrokhi K, Moshkelgosha S, Guo Q, He W, et al.
Clin Exp Immunol
. 2023 Apr;
213(1):138-154.
PMID: 37004176
The ability to induce tolerance would be a major advance in the field of solid organ transplantation. Here, we investigated whether autologous (congenic) hematopoietic stem cell transplantation (HSCT) could promote...
3.
Pancreatic Cancers with High Grade Tumor Budding Exhibit Hallmarks of Diminished Anti-Tumor Immunity
Sadozai H, Acharjee A, Gruber T, Gloor B, Karamitopoulou E
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33806316
Tumor budding is associated with epithelial-mesenchymal transition and diminished survival in a number of cancer types including pancreatic ductal adenocarcinoma (PDAC). In this study, we dissect the immune landscapes of...
4.
Sadozai H, Acharjee A, Eppenberger-Castori S, Gloor B, Gruber T, Schenk M, et al.
Front Immunol
. 2021 Mar;
12:643529.
PMID: 33679807
The aggressive biology and treatment refractory nature of pancreatic ductal adenocarcinoma (PDAC) significantly limits long-term survival. Examining the tumor microenvironment (TME) of long-term survivors (LTS) of PDAC offers the potential...
5.
Maibach F, Sadozai H, Seyed Jafari S, Hunger R, Schenk M
Front Immunol
. 2020 Oct;
11:2105.
PMID: 33013886
Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade (ICB) antibodies, have demonstrated the capacity of the immune system to fight cancer in a number of malignancies such as...
6.
Gruber T, Kremenovic M, Sadozai H, Rombini N, Baeriswyl L, Maibach F, et al.
JCI Insight
. 2020 Aug;
5(18).
PMID: 32841222
Myeloid cells orchestrate the antitumor immune response and influence the efficacy of immune checkpoint blockade (ICB) therapies. We and others have previously shown that IL-32 mediates DC differentiation and macrophage...
7.
Luft O, Khattar R, Farrokhi K, Ferri D, Yavorska N, Zhang J, et al.
Immunology
. 2018 Jan;
154(3):476-489.
PMID: 29341118
Persistent viruses evade immune detection by interfering with virus-specific innate and adaptive antiviral immune responses. Fibrinogen-like protein-2 (FGL2) is a potent effector molecule of CD4 CD25 FoxP3 regulatory T cells...
8.
Gorczynski R, Farrokhi K, Gorczynski C, Sadozai H, Zhu F, Khatri I
Immunology
. 2018 Jan;
154(3):465-475.
PMID: 29338084
We previously showed that congenic bone marrow transplantation (BMTx) post myeloablation augmented tissue allograft survival in association with increased regulatory T (Treg) cells of both host and bone marrow donor...
9.
Sadozai H, Gruber T, Hunger R, Schenk M
Front Immunol
. 2017 Dec;
8:1617.
PMID: 29276510
The global health burden associated with melanoma continues to increase while treatment options for metastatic melanoma are limited. Nevertheless, in the past decade, the field of cancer immunotherapy has witnessed...
10.
Gorczynski R, Sadozai H, Zhu F, Khatri I
Immunology
. 2016 Nov;
150(4):418-431.
PMID: 27859243
Significant barriers to transplantation exist for individuals who are pre-sensitized to donor antigen and have high titres of donor-reactive antibody. We report the effect of autologous bone marrow transplantation (BMTx)...